CD33 positive

P=N/A, N=165, Recruiting, Pfizer | Trial completion date: Nov 2027 --> Apr 2027 | Trial primary completion date: Nov 2027 --> Apr 2027

AML1-ETO fusion gene positive acute myeloid leukemia with basophilic granulocytosis is a rare type of leukemia, and its pathogenesis, diagnosis, treatment, and prognosis are unique. In-depth study of such cases, combined with the review of relevant literature, is helpful to further reveal the pathogenesis of leukemia, provide more evidence for clinical diagnosis and treatment, so as to improve the level of diagnosis and treatment and improve the prognosis of patients.

P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027

P1, N=21, Completed, Uma Borate | Active, not recruiting --> Completed

To date, only antibody-drug conjugates have reached regulatory approval, with gemtuzumab ozogamicin approved in combination with intensive induction and consolidation therapy for newly diagnosed CD33-positive AML...This review will introduce the current immunotherapy platforms under investigation in AML, starting with antibody-based approaches, followed by T-cell redirecting therapies, and culminating in an overview of immune resistance, the bone marrow microenvironment, and strategies toward personalized combinatorial immunotherapy. By synthesizing recent clinical data and mechanistic insights, including those from early CAR and T-cell engager trials, we aim to provide a translational framework for how immunotherapy might still reshape AML care-through integration of immune contexture of the bone marrow environment aiming for rational combinatorial approaches.

P1, N=20, Recruiting, First Affiliated Hospital of Zhejiang University

P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

Between March 2020 and February 2023, 34 consecutive fit CD33+ AML patients, median age 54.5 years (range, 25-75) were treated. This study confirms the efficacy and toxicity data reported in clinical trials, highlighting the feasibility of GO based chemotherapy also in patients older than 60 years and as a bridge to allo-HSCT.

AML-MR patient shows pancytopenia and increased proportion of blasts in smear of peripheral blood cells. Bone marrow cytology and pathological examination show significant proliferation of hematopoietic cells. FCM can detect myeloid progenitor cells and primitive/immature red blood cells, while chromosome karyotype analysis can detect three abnormal karyotypes.

Knocking out DNMT1 can enhance the inhibitory effect of NK cells on AML, which may be related to enhancing NK cell memory function.

P1, N=18, Active, not recruiting, Uma Borate | Trial primary completion date: Jun 2025 --> Aug 2024

We establish by both IGH NGS analysis and mutational profiling that the CLL and HS are clonally-related and posit that acquisition of KRAS p.G13D drove transdifferentiation. This has therapeutic implications for targeting the RAS-BRAF-MAPK-ERK pathway.